Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combining radium-223 with other types of treatment and how to best optimize the use of the drug alone.

Michael Morris, MD, discusses the potential of radium-223 and how the agent could be successful and impactful in metastatic castration-resistant prostate cancer.

Robert J. Motzer, MD, discusses nivolumab's impact for renal cell carcinoma treatment.

The prospect of combining PD-1 inhibitors with existing therapies, particularly brentuximab vedotin, is emerging as the most exciting new development in advancing the treatment of patients with Hodgkin lymphoma, raising the possibility of improving the cure rates in a disease where standard strategies have already produced notable results.

The American Cancer Society now recommends that women at an average risk of breast cancer should wait to undergo annual screening mammography until they reach the age of 45.

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy agents in the treatment of patients with neuroendocrine carcinoma.

Dr. Noah Kauff discusses how hysterectomy, in addition to standard risk-reducing salpingo-oophorectomy (RRSO) measures, should be considered in BRCA+women to reduce the risk of serous uterine cancers.

Leonard Saltz, MD, discusses antiangiogenesis and the use of VEGF inhibitors in colorectal cancer.

The FDA has granted an accelerated approval to the combination of nivolumab and ipilimumab as a treatment for patients with BRAF V600 wild-type unresectable or metastatic melanoma.

The characterization of molecular abnormalities implicated in the tumorigenesis of sarcomas is being increasingly applied to the classification, prognostication and, in particular situations, management of these diseases.

Noah D. Kauff, MD, FACOG, gynecologist and geneticist, director, Ovarian Cancer Screening and Prevention, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the main challenges in treating uterine cancer.

The FDA has approved the antibody-drug conjugate brentuximab vedotin as a consolidation therapy following autologous stem cell transplantation in patients with Hodgkin lymphoma who are at risk of relapse or progression.

Lee M. Krug, MD, associate attending physician, Division of Thoracic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses a phase I study examining intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion.

Germline mutations in PALB2 have recently been shown to increase lifetime risk of pancreatic cancer and breast cancer, among other types.

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase II study examining bevacizumab combined with CRLX101 in patients with advanced renal cell carcinoma.

Jedd D. Wolchok, MD, discusses the unique design and goals of the CheckMate-067 trial, and what its results mean for patients with advanced melanoma going forward.

Jedd Wolchok, MD, chief, of Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center discusses combining targeted and immunotherapies.

As immunotherapy agents enter into greater clinical use in oncology, clinicians are learning to manage immune-related adverse events related to the mechanism of action of these new drugs.

The sheer number of survivors- nearly 15 million in the United States, or 4% of the population-has brought greater attention to ensuring that cancer treatment does not cause other harms, since cancer patients are not only living but also living longer.

Population-based cancer screening using genetic sequencing technology is an idea worthy of careful consideration, but there are many challenges to implementing such a program.

Jedd D. Wolchok, MD, PhD, played an important role in the development of ipilimumab, the first drug to target an immune checkpoint as an anticancer strategy. He was honored in the Melanoma category with a 2014 Giants of Cancer Care® award.

A biomarker panel containing circulating tumor cell number and LDH level was shown to be a surrogate for overall survival in patients with metastatic castration-resistant prostate cancer.

Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the challenges with approaching the topic of obesity in patients with cancer.

Jedd Wolchok, MD, PhD, chief, of Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses the toxicities associated with immunotherapy.

Mario E. Lacouture, MD, a dermatologist with Memorial Sloan Kettering Cancer Center, explains how providers can manage adverse events that result from melanoma therapies.

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses early efficacy signals in the phase I/II DART study.

In an analysis of phase III data, the 5-year survival rate with ipilimumab plus dacarbazine in patients with advanced melanoma was 18.2% versus 8.8% with dacarbazine alone.

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the challenges oncologists face with T-cell lymphoma.

Amid continuing excitement over the potential for PD-1 pathway immune checkpoint blockade strategies in anticancer therapies, research presented at the 2014 American Society of Hematology (ASH) Annual Meeting helped established a foundation for the use of anti- PD-1/PD-L1 agents in hematologic malignancies.

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses remaining questions regarding immunotherapies for the treatment of melanoma.